By Budi Oetomo Narendra 
Medications are designed to treat diseases and relieve symptoms, but some can also produce unintended effects that put patients at risk. While side effects are common with many treatments, researchers at the Norwegian University of Science and Technology (NTNU) have identified a particularly concerning possibility involving a widely used class of anti-inflammatory drugs. Their new findings suggest that these medications, known as Janus kinase (JAK) inhibitors, may inadvertently make it easier for certain viruses to infect cells and spread throughout the body, potentially compromising patient safety and complicating public health responses to viral outbreaks.
The Core Discovery: JAK Inhibitors and Viral Vulnerability
The central revelation from the NTNU study, published in NAR Molecular Medicine, is that JAK inhibitors, while highly effective in controlling inflammation, possess a significant trade-off: they can suppress critical immune pathways that normally protect healthy cells from viral attacks. Professor Denis Kainov from NTNU’s Department of Clinical and Molecular Medicine articulated the gravity of the finding: "We have found a surprising and potentially serious side effect of a class of anti-inflammatory drugs. They can help viruses spread more easily in the body." This discovery shifts the understanding of the known infection risks associated with these drugs, highlighting a specific mechanism of increased viral susceptibility.
The medications at the center of these findings are widely prescribed for a range of autoimmune and inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and atopic dermatitis. By modulating the immune system to reduce inflammatory responses, these drugs offer significant relief for millions of patients globally. However, the NTNU team’s research indicates that this immune modulation may come at the cost of weakening the body’s intrinsic antiviral defenses. Among the viruses identified that could potentially benefit from this vulnerability are Rift Valley fever virus, influenza A, adenovirus, and SARS-CoV-2, the virus responsible for the COVID-19 pandemic. The inclusion of such globally significant pathogens underscores the potential far-reaching implications of this research.
Understanding JAK Inhibitors: A Brief Overview
Janus kinase (JAK) inhibitors represent a class of targeted synthetic disease-modifying antirheumatic drugs (tsDMARDs) that have revolutionized the treatment landscape for various chronic inflammatory and autoimmune diseases. Unlike traditional immunosuppressants that broadly suppress the immune system, JAK inhibitors specifically target intracellular signaling pathways known as the JAK-STAT (Signal Transducer and Activator of Transcription) pathway. This pathway is crucial for the transmission of signals from cell surface receptors for cytokines and growth factors, which play pivotal roles in immune cell function, inflammation, and hematopoiesis.
By blocking the activity of specific JAK enzymes (JAK1, JAK2, JAK3, TYK2), these drugs interfere with the signaling cascade that would otherwise lead to the activation of immune cells and the production of pro-inflammatory mediators. For example, in rheumatoid arthritis, excessive inflammation leads to joint damage. JAK inhibitors work by reducing the inflammatory signals that drive this process, thereby alleviating symptoms and slowing disease progression. First approved in 2012 with tofacitinib (Xeljanz), the class has expanded to include drugs like baricitinib (Olumiant), upadacitinib (Rinvoq), and others, each with varying selectivity for different JAK enzymes, but all sharing the core mechanism of immunomodulation. The global market for JAK inhibitors has grown exponentially, reflecting their efficacy and widespread adoption, with projections placing their annual sales in the tens of billions of dollars.
The Immune System’s Antiviral Arsenal and How JAK Inhibitors Interfere
The human immune system has evolved sophisticated mechanisms to detect and neutralize viral threats. A cornerstone of this defense is the innate immune response, particularly the production of type I interferons (IFN-α and IFN-β). When a cell detects a viral invasion, it releases interferons, which then bind to receptors on neighboring cells. This binding triggers the JAK-STAT pathway, leading to the activation of specific genes that produce antiviral proteins. These proteins establish an "antiviral state" in uninfected cells, making them more resistant to viral entry and replication, effectively acting as an early warning and containment system.
Erlend Ravlo, a PhD research fellow at NTNU and first author of the NAR Molecular Medicine article, elaborated on this critical interaction: "JAK inhibitors are often prescribed for autoimmune diseases and inflammatory conditions such as rheumatoid arthritis. Although these medications can be highly effective at reducing inflammation, their benefits come with an important trade-off. By suppressing certain immune responses, they can also interfere with the mechanisms that normally protect the body from viral infections. In particular, the drugs suppress an important immune signalling pathway that helps protect healthy cells from viral attacks."
The NTNU research team, including Aleksandr Ianevski, an NTNU researcher and coauthor, meticulously investigated how JAK inhibitors, including baricitinib, specifically reduce the activity of genes crucial for fighting viral infections. "These genes play a crucial role in the body’s response to viral infections," Ianevski stated. By dampening this interferon-mediated antiviral signaling, JAK inhibitors effectively lower the cellular defenses, creating an environment where viruses can more easily gain a foothold and proliferate. This mechanism explains why patients on these drugs might face an increased risk of severe or prolonged viral infections, going beyond a general immunosuppression to a targeted disruption of innate antiviral immunity.
A Chronology of JAK Inhibitors and Emerging Safety Profiles
The journey of JAK inhibitors from laboratory discovery to widespread clinical use spans several decades. The initial conceptualization of Janus kinases and their role in cytokine signaling began in the late 1980s and early 1990s. The first oral JAK inhibitor, tofacitinib, received FDA approval in 2012 for rheumatoid arthritis, marking a significant milestone. Subsequent approvals for other JAK inhibitors, such as baricitinib (2018) and upadacitinib (2019), expanded their indications to include conditions like psoriatic arthritis, ulcerative colitis, and atopic dermatitis.
From their early days, a known class effect of JAK inhibitors has been an increased risk of infections, given their immunosuppressive nature. Regulatory bodies, including the FDA and the European Medicines Agency (EMA), have consistently included warnings about the potential for serious infections, including opportunistic infections, in the prescribing information for these drugs. Patients are routinely screened for latent infections (e.g., tuberculosis) before starting therapy and monitored throughout treatment. However, the NTNU study introduces a more nuanced understanding of this risk, pinpointing a specific molecular pathway through which these drugs may not just increase susceptibility but actively facilitate viral replication and spread. This distinction is crucial, as it suggests a more direct impairment of antiviral defenses than previously understood, particularly against the specific viral classes identified.
The COVID-19 pandemic also brought JAK inhibitors into the spotlight, with baricitinib notably receiving emergency use authorization from the FDA for the treatment of hospitalized COVID-19 patients requiring supplemental oxygen. Its anti-inflammatory properties were thought to mitigate the cytokine storm associated with severe COVID-19. This paradoxical use highlights the complex interplay of inflammation and infection, where modulating the immune response can be both beneficial and detrimental depending on the specific context and timing. The NTNU findings add another layer of complexity to this therapeutic balancing act, suggesting that while JAK inhibitors might quell the inflammatory damage of a severe viral infection, they could, under different circumstances, exacerbate the initial viral spread.
Methodology and Robustness of the NTNU Research
To arrive at their conclusions, the NTNU scientists employed a sophisticated array of advanced virology methods, gene expression analysis, and cutting-edge organoid technology. Their experiments were not limited to simple cell cultures but included cells from vital human organs such as the lungs, eyes, and brain, along with miniature organ models grown in the laboratory. Organoids, three-dimensional cellular structures that mimic the architecture and function of actual organs, provide a highly relevant experimental platform for studying drug effects and disease mechanisms in a more physiological context than traditional 2D cell cultures.
This multi-pronged approach allowed the team to examine precisely how JAK inhibitors affect antiviral defenses across different types of human tissue, providing robust evidence for their findings. By combining the observation of viral spread with detailed analysis of gene activity, they could directly link the drug’s action on immune pathways to its impact on viral infectivity. "Although JAK inhibitors are effective in the treatment of inflammation, this shows that they can pose a hidden risk for patients who have latent or active viral infections," Ravlo cautioned, emphasizing the importance of this comprehensive investigative approach.
Implications for Clinical Practice and Patient Safety
The findings from NTNU carry significant implications for clinical practice, patient management, and public health strategies, particularly during periods of increased viral transmission or outbreaks. Healthcare professionals prescribing JAK inhibitors will need to carefully weigh the therapeutic benefits against the potential for increased viral vulnerability.
- Enhanced Vigilance: The research suggests a need for heightened clinical awareness, especially when patients on JAK inhibitors present with viral symptoms or during seasonal viral epidemics (e.g., influenza) or pandemics.
- Personalized Risk Assessment: Prescribing decisions may require a more personalized risk-benefit assessment, considering the patient’s individual viral exposure risk, vaccination status, and the prevalence of circulating viruses.
- Monitoring and Education: Patients taking JAK inhibitors should be thoroughly educated about the potential for increased viral susceptibility and encouraged to report any signs of viral infection promptly. More rigorous monitoring for viral infections might become standard.
- Guideline Updates: Regulatory bodies like the FDA and EMA may consider updating prescribing guidelines and patient information leaflets for JAK inhibitors to specifically address this newly identified mechanism of increased viral spread, refining existing warnings about general infection risk.
- Pharmacovigilance: Pharmaceutical companies manufacturing JAK inhibitors will likely engage in further pharmacovigilance studies and potentially support additional research to better characterize these risks. Their statements would typically emphasize the proven benefits of their medications while acknowledging the importance of ongoing safety research and adherence to prescribing guidelines.
Broader Scientific Landscape and Future Directions
Beyond immediate clinical adjustments, the NTNU study opens new avenues for scientific inquiry and therapeutic innovation.
- Drug Development: The findings could spur the development of more selectively targeted JAK inhibitors that maintain anti-inflammatory efficacy while minimizing interference with crucial antiviral pathways. Alternatively, combination therapies that pair JAK inhibitors with prophylactic antiviral agents might be explored.
- Vaccine and Antiviral Research: Paradoxically, the very property of JAK inhibitors that makes them concerning in clinical settings could be harnessed in controlled laboratory environments. Their ability to facilitate viral spread in cells could make them valuable tools for scientists developing new vaccines or screening potential antiviral medications, allowing for more efficient propagation of viruses for research purposes.
- Long-Term Observational Studies: The need for long-term observational studies, registries, and real-world evidence to further quantify the clinical impact of these findings on patient outcomes is paramount. This would help ascertain the frequency and severity of viral infections in patients on JAK inhibitors compared to other treatments or the general population.
- Global Health Perspective: For regions endemic with viruses like Rift Valley fever, understanding how widely used anti-inflammatory drugs might influence disease transmission and severity is crucial for public health planning and outbreak management.
"We recommend further studies to better understand how the drugs can be used optimally, especially during virus outbreaks or pandemics," Ianevski concluded, emphasizing the ongoing commitment to refining our understanding of these powerful medications. Professor Magnar Bjørås of the Department of Clinical and Molecular Medicine provided significant scientific expertise and secured most of the funding for this impactful research. Additional financial support came from critical sources including the Central Norway Regional Health Authority, the South-Eastern Norway Regional Health Authority, the Research Council of Norway, and the Swedish Research Council, highlighting a collaborative commitment to advancing medical knowledge for public good.
In conclusion, the NTNU research represents a critical advancement in understanding the complex interplay between immunomodulatory drugs and viral susceptibility. While JAK inhibitors remain indispensable for managing chronic inflammatory diseases, this new knowledge underscores the perpetual balance between therapeutic benefit and potential risk, demanding careful consideration from both prescribers and patients, and paving the way for more informed and safer medical practices in the future.
